Allergy Therapeutics expects revenue growth after "strong" first half
(Alliance News) - Allergy Therapeutics PLC shares declined on Monday, despite the firm saying it expects to report increased revenue for its first half. Read More
| Price | 11.60p on 20-01-2026 at 06:00:01 |
|---|---|
| Change | 0.00p 0% |
| Buy | 0.00p |
| Sell | 0.00p |
| Last Trade: | Buy 4,000.00 at 11.60p |
| Day's Volume: | 0 |
| Last Close: | 11.60p |
| Open: | 0.00p |
| ISIN: | GB00B02LCQ05 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 5.25p - 12.10p |
| Market Capitalisation: | £712.41m |
| VWAP: | 0.00p |
| Shares in Issue: | 6.14b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Allergy Thera. (AGY) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 4,000 | 11.60p | Suspected BUY Trade |
16:35:11 - 19-Jan-26 |
| Buy* | 25,974 | 11.55p | Ordinary |
15:40:18 - 19-Jan-26 |
| Buy* | 17,176 | 11.6437p | Ordinary |
15:34:54 - 19-Jan-26 |
| Unknown* | 185,000 | 10.9162p | Negotiated Trade |
12:47:53 - 19-Jan-26 |
| Unknown* | 185,000 | 10.90p | Negotiated Trade |
12:47:42 - 19-Jan-26 |
| Buy* | 5,000 | 11.699p | Ordinary |
12:27:23 - 19-Jan-26 |
| Buy* | 1 | 11.699p | Ordinary |
11:26:46 - 19-Jan-26 |
| Sell* | 9,184 | 10.8888p | Ordinary |
11:10:39 - 19-Jan-26 |
| Sell* | 3,000 | 10.8888p | Ordinary |
09:44:42 - 19-Jan-26 |
| Buy* | 2,500 | 11.90p | Suspected BUY Trade |
09:00:15 - 19-Jan-26 |
Allergy Thera. (AGY) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 19th Jan 2026 7:00 am | RNS | Half Year Trading Update |
| 6th Jan 2026 7:00 am | RNS | Notice of 2025 Annual General Meeting |
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 16th Dec 2025 7:00 am | RNS | Grassmuno® marketing authorisation in Germany |
| 12th Dec 2025 7:00 am | RNS | Authority for allotment of New Shares |
| 11th Dec 2025 7:00 am | RNS | Prelim Results and publication of Annual Report |
| 9th Dec 2025 7:00 am | RNS | Primary Safety Endpoint Met in PROTECT trial |
| 6th Nov 2025 7:22 am | RNS | Company to Evaluate Dual Listing on HKEX |
| 30th Oct 2025 7:00 am | RNS | G308 Phase III Year 2 Patient Screening Starts |